Key result
A standardized MxA protein measurement-based assay using IFN-β1a as the challenge antigen demonstrated 100% concordance across laboratories in identifying neutralizing antibody status.
Population
62 serum samples from NAb-positive multiple sclerosis patients undergoing therapy with Betaseron, Avonex, or…
Design
Other, blind panel (coded)
Authors
Loading...
Supports inter-laboratory NAb assay standardization in MS; leaves open effects on treatment decisions.
Adoption of a standardized MxA protein assay using IFN-β1a as the challenge antigen improves comparability of neutralizing antibody data between laboratories for MS patients.
Wadhwa et al. (2013) studied Multiple Sclerosis (n=62). Standardized MxA protein measurement-based assay using IFN-β1a vs. Assay using IFN-β1b was evaluated on Concordance across laboratories for NAb detection. A standardized MxA protein measurement-based assay using IFN-β1a as the challenge antigen demonstrated 100% concordance across laboratories in identifying neutralizing antibody status.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: